Treatment of bone and joint infections caused by Gram-negative bacilli with a cefepime-fluoroquinolone combination

被引：44
作者：
Legout, L.
Senneville, E.
Stern, R.
Yazdanpanah, Y.
Savage, C.
Roussel-Delvalez, M.
Rosele, B.
Migaud, H.
Mouton, Y.
机构：
[1] Univ Lille, Dron Hosp, Div Infect Dis, Tourcoing, France
[2] Univ Hosp Geneva, Geneva, Switzerland
[3] Univ Lille, Salengro Hosp, Dept Microbiol, Lille, France
[4] Univ Lille, Salengro Hosp, Dept Orthopaed Surg, Lille, France
来源：
CLINICAL MICROBIOLOGY AND INFECTION | 2006年 / 12卷 / 10期
关键词：
bone infections; cefepime; fluoroquinolone; Gram-negative bacteria; joint infections; treatment;
D O I：
10.1111/j.1469-0691.2006.01523.x
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
A 3-year retrospective study evaluated the effectiveness and safety of cefepime plus a fluoroquinolone for treating bone and joint infections caused by Gram-negative bacilli (GNB) in 28 patients. Intra-operative cultures yielded primarily Pseudomonas spp. and Enterobacter cloacae. Full recovery (cure) was observed in 79% of patients. There were no serious adverse effects and no resistant organisms were isolated. The results of the study confirmed the safety and effectiveness of cefepime combined with a fluoroquinolone for the treatment of bone and joint infections caused by Gram-negative bacilli.
引用
收藏
页码：1030 / 1033
页数：5
相关论文
共 20 条
[1]   CEFTAZIDIME AS SINGLE-AGENT THERAPY FOR GRAM-NEGATIVE AEROBIC BACILLARY OSTEOMYELITIS [J].
BACH, MC ;
COCCHETTO, DM .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1987, 31 (10) :1605-1608
[2]   Diffusion of cefepime into cancellous and cortical bone tissue [J].
Breilh, D ;
Boselli, E ;
Bel, JC ;
Chassard, D ;
Saux, MC ;
Allaouchiche, B .
JOURNAL OF CHEMOTHERAPY, 2003, 15 (02) :134-138
[3]   TREATMENT OF PSEUDOMONAS-AERUGINOSA-INFECTED ORTHOPEDIC PROSTHESES WITH CEFTAZIDIME CIPROFLOXACIN ANTIBIOTIC COMBINATION [J].
BROUQUI, P ;
ROUSSEAU, MC ;
STEIN, A ;
DRANCOURT, M ;
RAOULT, D .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1995, 39 (11) :2423-2425
[4]  
DRANCOURT M, 1982, ANTIMICROB AGENTS CH, V21, P62
[5]   In vitro activity of combination therapy with cefepime, piperacillin-tazobactam, or meropenem with ciprofloxacin against multidrug-resistant Pseudomonas aeruginosa strains [J].
Erdem, I ;
Kucukercan, M ;
Ceran, N .
CHEMOTHERAPY, 2003, 49 (06) :294-297
[6]   Chronic osteomyelitis caused by multi-resistant Gram-negative bacteria: evaluation of treatment with newer quinolones after prolonged follow-up [J].
Galanakis, N ;
Giamarellou, H ;
Moussas, T ;
Dounis, E .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1997, 39 (02) :241-246
[7]   Ciprofloxacin, lomefloxacin, or levofloxacin as treatment for chronic osteomyelitis [J].
Greenberg, RN ;
Newman, MT ;
Shariaty, S ;
Pectol, RW .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (01) :164-166
[8]   In vitro and in vivo activities of levofloxacin against biofilm-producing Pseudomonas aeruginosa [J].
Ishida, H ;
Ishida, Y ;
Kurosaka, Y ;
Otani, T ;
Sato, K ;
Kobayashi, H .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (07) :1641-1645
[9]   Synergistic activities of moxifloxacin combined with piperacillin-tazobactam or cefepime against Klebsiella pneumoniae, Enterobacter cloacae, and Acinetobacter baumannii clinical isolates [J].
Jung, R ;
Husain, M ;
Choi, MK ;
Fish, DN .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (03) :1055-1057
[10]   IMIPENEM CILASTATIN IN THE TREATMENT OF OSTEOMYELITIS [J].
MACGREGOR, RR ;
GENTRY, LO .
AMERICAN JOURNAL OF MEDICINE, 1985, 78 (6A) :100-103
12